C-ACTHSylvatica Biotech
cryobanking, supercooling, organ preservation
biobanking
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ACTH
C-ACTHC-ACTHcryobanking, supercooling, organ preservation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Sylvatica Biotech cryobanking, supercooling, organ preservation
Sylvatica is a cryobanking R&D company developing technologies to increase the availability and quality of organs and tissues for transplantation. The company says it aims to transform organ transplantation, drug discovery, and regenerative medicine through technology that controls biological time. Its highlighted science includes high-subzero preservation of human livers and supercooling approaches that extend liver preservation time.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Sylvatica Biotech — Early mechanism · Lower middle. Derived deterministically from 3 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic